CNCR vs. BBC

Last updated Jun 3, 2026

CNCR (Loncar Cancer Immunotherapy ETF) and BBC (Virtus LifeSci Biotech Clinical Trials ETF) are both Health & Biotech Equities funds - CNCR tracks the Loncar Cancer Immunotherapy Index while BBC tracks the LifeSci Biotechnology Clinical Trials Index. Both are passively managed. Both charge a 0.79% expense ratio.

Performance

CNCR vs. BBC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Loncar Cancer Immunotherapy ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

BBC

• 1D: -4.90%
• 1M: -4.81%
• YTD: 8.17%
• 6M: 20.12%
• 1Y: 123.11%
• 3Y*: 19.82%
• 5Y*: -2.05%
• 10Y*: 7.60%

*Multi-year figures are annualized to reflect compound growth (CAGR)

CNCR vs. BBC - Yearly Performance Comparison

	2026 (YTD)
CNCR Loncar Cancer Immunotherapy ETF	0.00%
BBC Virtus LifeSci Biotech Clinical Trials ETF	2.05%

CNCR vs. BBC - Sectors Allocation Comparison

Sectors	CNCR	BBC
Healthcare	96.6%	100.0%
Financial Services	3.3%	-
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Industrials	-	-
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

CNCR vs. BBC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BBC

BBC Risk / Return Rank: 90
BBC Sharpe Ratio Rank: 93
BBC Sortino Ratio Rank: 89
BBC Omega Ratio Rank: 79
BBC Calmar Ratio Rank: 96
BBC Martin Ratio Rank: 94

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CNCR vs. BBC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Loncar Cancer Immunotherapy ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	CNCR	BBC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	3.49	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.05	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.20	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	0.12	—

Drawdowns

CNCR vs. BBC - Drawdown Comparison

The maximum CNCR drawdown since its inception was 0.00%, smaller than the maximum BBC drawdown of -76.85%. Use the drawdown chart below to compare losses from any high point for CNCR and BBC.

Drawdown Indicators

	CNCR	BBC	Difference
Max Drawdown Largest peak-to-trough decline	0.00%	-76.85%	+76.85%
Max Drawdown (1Y) Largest decline over 1 year	—	-15.10%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-54.45%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-72.44%	—
Max Drawdown (10Y) Largest decline over 10 years	—	-76.85%	—
Current Drawdown Current decline from peak	0.00%	-30.57%	+30.57%
Average Drawdown Average peak-to-trough decline	0.00%	-37.14%	+37.14%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	4.66%	—

Volatility

Volatility by Period

	CNCR	BBC	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	11.21%	—
Volatility (6M) Calculated over the trailing 6-month period	—	26.65%	—
Volatility (1Y) Calculated over the trailing 1-year period	0.00%	35.74%	-35.74%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	0.00%	39.31%	-39.31%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	0.00%	37.75%	-37.75%

CNCR vs. BBC - Expense Ratio Comparison

Both CNCR and BBC have an expense ratio of 0.79%.

Dividends

CNCR vs. BBC - Dividend Comparison

CNCR has not paid dividends to shareholders, while BBC's dividend yield for the trailing twelve months is around 1.57%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BBC Virtus LifeSci Biotech Clinical Trials ETF	1.57%	1.70%	1.00%	0.34%	0.00%	0.00%	0.00%	0.00%	0.00%	2.09%	0.00%	0.51%
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions

Which ETF is better, CNCR or BBC?

Both ETFs have the same 0.79% expense ratio. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, CNCR or BBC?

CNCR and BBC have the same expense ratio: 0.79% per year.

Which ETF pays a higher dividend yield, CNCR or BBC?

BBC has the higher dividend yield at 1.57%, compared with 0.00% for CNCR.

What is the main difference between CNCR and BBC?

CNCR tracks Loncar Cancer Immunotherapy Index, while BBC tracks LifeSci Biotechnology Clinical Trials Index. They also come from different issuers: Exchange Traded Concepts and Virtus Investment Partners.